New cancer vaccine delivers stunning result against one of the deadliest skin cancers

This material may not be published, broadcast, rewritten, or redistributed. ©2026 FOX News Network, LLC. All rights reserved. Quotes displayed in real-time or delayed by at least 15 minutes. Market data provided by Factset. Powered and implemented by FactSet Digital Solutions. Legal Statement. Mutual Fund and ETF data provided by LSEG. A new injectable therapy is showing positive results in reducing melanoma throughout a five-year period. The personalized mRNA cancer therapy, combined with the cancer immunotherapy drug KEYTRUDA, is a collaboration between Merck and Moderna. A new injectable therapy is showing positive results in reducing melanoma throughout a five-year period. The personalized mRNA cancer therapy, called intismeran autogene, combined with the cancer immunotherapy drug KEYTRUDA (pembrolizumab), is a collaboration between Merck and Moderna. The results from the phase 2b KEYNOTE-942 study were presented at the American Society of Clinical Oncology (ASCO) Annual Meeting in Chicago on May 27. After about a five-year follow-up, the combo drug was found to reduce the risk of melanoma recurrence or death by 49% compared to pembrolizumab alone. The researchers analyzed data